Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 31

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 31
---
 to be a contingent liability- In July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (Sellers) regarding the 2014 share purchase agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately $140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of $46m in favour of the Sellers.- In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court (Court) to set aside the arbitration award.- In April 2025, the Court ruled in favour of AstraZeneca, annulled the arbitration award, and referred the dispute back to the same arbitration panel for a second determination.- In May 2025, the Sellers appealed the Court's decision to the German Federal Court of Justice. AstraZeneca also appealed the decision to refer the dispute back to the same arbitration panel.​Seroquel XRAntitrust Litigation, USA provision has been taken- In 2019, AstraZeneca was named in several related complaints now proceeding in US District Court in Delaware (District Court), including several putative class action lawsuits that were purportedly brought on behalf of classes of direct purchasers or end payors of Seroquel XR, that allege AstraZeneca and generic drug manufacturers violated US antitrust laws when settling patent litigation related to Seroquel XR.- In July 2022, the District Court dismissed claims relating tooneof the generic manufacturers while allowing claims relating to the second generic manufacturer to proceed.- In September 2024, AstraZeneca reached a settlement agreement withoneof the plaintiff classes which the court approved.-In May 2025, AstraZeneca resolved the matter with all remaining plaintiffs for a total payment of $97M. The Court must approve the class-related portion of the settlement before the matter is concluded.​Syntimmune Milestone Litigation, USConsidered to be a contingent liability-In connection with AstraZeneca's acquisition of Syntimmune, Inc. (Syntimmune) in December 2020, AstraZeneca was served with a lawsuit filed by the stockholders' representative for Syntimmune in Delaware state court that alleged, among other things, breaches of the 2018 merger agreement (Merger Agreement).- The stockholders' representative alleges that AstraZeneca failed